The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I, open-label, cohort study of two doses of coxsackievirus A21 given intratumorally in stage IV melanoma.
D. Shafren
Employment or Leadership Position - Viralytics ; Viralytics (I)
Consultant or Advisory Role - Viralytics
Stock Ownership - Viralytics
Research Funding - Viralytics
Other Remuneration - Viralytics
B. M. Smithers
No relevant relationships to disclose
M. Formby
No relevant relationships to disclose